Literature DB >> 14657844

Current management of atopic dermatitis and interruption of the atopic march.

Mark Boguniewicz1, Lawrence F Eichenfield, Thomas Hultsch.   

Abstract

Treatment of atopic dermatitis requires a comprehensive approach that includes evaluation of potential triggers and education of the patient and family regarding proper avoidance measures. Hydration of the skin and maintenance of an intact skin barrier remain integral to proper management. Although topical corticosteroids have been a mainstay of anti-inflammatory therapy, the newer topical calcineurin inhibitors offer advantages for treatment of this chronic, relapsing disease. Studies aimed at defining optimal combination therapy and early intervention might change the treatment paradigm for atopic dermatitis.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 14657844     DOI： 10.1016/j.jaci.2003.09.031

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN： 0091-6749            Impact factor:   10.793


  10 in total

1.  Accident and emergency: a gateway to improve the management of atopic disease.

Authors:  S Treffene; R Paget; I Maconochie
Journal:  Arch Dis Child       Date:  2006-06       Impact factor: 3.791

2.  Pathways to managing atopic dermatitis: consensus from the experts.

Authors:  Mark G Lebwohl; James Q Del Rosso; William Abramovits; Brian Berman; David E Cohen; Emma Guttman; Anthony J Mancini; Lawrence A Schachner
Journal:  J Clin Aesthet Dermatol       Date:  2013-07

Review 3.  Topical calcineurin inhibitors in pediatric atopic dermatitis: a critical analysis of current issues.

Authors:  Seth J Orlow
Journal:  Paediatr Drugs       Date:  2007       Impact factor: 3.022

4.  Dexamethasone and FK506 inhibit expression of distinct subsets of chemokines in human mast cells.

Authors:  Atsushi Kato; Regina T Chustz; Takahisa Ogasawara; Marianna Kulka; Hirohisa Saito; Robert P Schleimer; Kenji Matsumoto
Journal:  J Immunol       Date:  2009-06-01       Impact factor: 5.422

Review 5.  New insights into atopic dermatitis.

Authors:  Donald Y M Leung; Mark Boguniewicz; Michael D Howell; Ichiro Nomura; Qutayba A Hamid
Journal:  J Clin Invest       Date:  2004-03       Impact factor: 14.808

6.  Treatment of Atopic Dermatitis From the Perspective of Traditional Persian Medicine: Presentation of a Novel Therapeutic Approach.

Authors:  Rasool Choopani; Mehrzad Mehrbani; Alireza Fekri; Mitra Mehrabani
Journal:  J Evid Based Complementary Altern Med       Date:  2015-08-09

7.  Erythrodermic atopic dermatitis with late onset--case presentation.

Authors:  Cristina Lancrajan; Roxana Bumbacea; Calin Giurcaneanu
Journal:  J Med Life       Date:  2010 Jan-Mar

8.  Efficacy of topical azathioprine and betamethasone versus betamethasone-only emollient cream in 2-18 years old patients with moderate-to-severe atopic dermatitis: A randomized controlled trial.

Authors:  Fariba Iraji; Sadaf Farhadi; Gita Faghihi; Fatemeh Mokhtari; Akram Basiri; Tohid Jafari-Koshki; Mohammad Ali Nilforoushzadeh
Journal:  Adv Biomed Res       Date:  2015-10-07

9.  The imbalance in serum concentration of Th-1- and Th-2-derived chemokines as one of the factors involved in pathogenesis of atopic dermatitis.

Authors:  Joanna Narbutt; Aleksandra Lesiak; Anna Sysa-Jedrzeiowska; Marcin Zakrzewski; Jarosław Bogaczewicz; Iwona Stelmach; Piotr Kuna
Journal:  Mediators Inflamm       Date:  2009-07-22       Impact factor: 4.711

10.  Leukotriene receptor antagonists for eczema.

Authors:  Leila Ferguson; Masaki Futamura; Efstratios Vakirlis; Reiji Kojima; Hatoko Sasaki; Amanda Roberts; Rintaro Mori
Journal:  Cochrane Database Syst Rev       Date:  2018-10-21
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.